Breaking News

Almac, TTP Form FLT Pact

January 7, 2013

Aims to provide enhanced screening performance

Almac and TTP Labtech have formed an alliance in the field of fluorescence lifetime (FLT) technology to provide enhanced screening performance. The alliance aims to provide customers with access to a broad range of biological applications coupled with the next generation of microplate reader technology.
According to the companies, FLT as a reading modality offers a robust, antibody-free, homogeneous assay platform that enables the user to avoid interference from fluorescent compounds within a screening library. Almac’s FLEXYTE assays now have FLT technology to provide a more efficient and economical platform for screening and profiling. The evolving assay platform offers solutions for many therapeutic target classes including: kinases, proteases, phosphatases, DUB, and epigenetic targets.
TTP Labtech’s Ameon system is a next-generation FLT reader technology, offering real-time decay curve analysis, faster and more precise data quality, and can be integrated into HTS workflows, according to the company.
“The development of the Ameon reader by TTP Labtech has introduced an exciting new dimension to FLT technology and we are pleased that Almac’s FLEXYTE customers will be able to benefit from this advance in reader technology,” said Dr. Stephen Barr, president and managing director of Almac Sciences.
“We are excited by the potential of the FLEXYTE and Ameon reader combination to deliver robust, cost-effective screening results and enhanced productivity through better discrimination of lead compounds,” said Dr. Wayne Bowen, chief scientific officer of TTP Labtech.
  • Analytical Testing Outsourcing Trends Update

    Analytical Testing Outsourcing Trends Update

    January 26, 2017
    Spurred by many factors, global analytical testing services market is experiencing rapid growth in the range of 11% per year

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research